Rabbit Recombinant Monoclonal PCIF1 antibody. Suitable for IP, WB and reacts with Human, Rat samples. Cited in 1 publication.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59.94% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
ICC/IF | IP | WB | IHC-P | Flow Cyt (Intra) | |
---|---|---|---|---|---|
Human | Not recommended | Tested | Tested | Not recommended | Not recommended |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Expected | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/30 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info 1/1000 | Notes - |
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Human, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Cap-specific adenosine methyltransferase that catalyzes formation of N(6),2'-O-dimethyladenosine cap (m6A(m)) by methylating the adenosine at the second transcribed position of capped mRNAs (PubMed:30467178, PubMed:30487554, PubMed:31279658, PubMed:31279659, PubMed:33428944). Recruited to the early elongation complex of RNA polymerase II (RNAPII) via interaction with POLR2A and mediates formation of m6A(m) co-transcriptionally (PubMed:30467178).
C20orf67, CAPAM, PPP1R121, PCIF1, mRNA (2'-O-methyladenosine-N(6)-)-methyltransferase, Cap-specific adenosine methyltransferase, Phosphorylated CTD-interacting factor 1, Protein phosphatase 1 regulatory subunit 121, hCAPAM, hPCIF1
Rabbit Recombinant Monoclonal PCIF1 antibody. Suitable for IP, WB and reacts with Human, Rat samples. Cited in 1 publication.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59.94% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
PCIF1 also known as Phosphorylated CTD-interacting factor 1 is a protein with a mass of around 66 kDa. It functions mechanically as an enzyme that methylates the 2'-O position of RNA cap structures modulating mRNA stability and translation. You find PCIF1 expression predominantly in the nucleus of human cells where it interacts with the C-terminal domain of RNA polymerase II. Its role is essential in RNA processing impacting the regulation of gene expression at a post-transcriptional level.
PCIF1 modifies RNA molecules influencing mRNA cap structure formation and methylation. This activity is a part of the cap-binding complex which ensures proper RNA maturation and function. By interacting with the cap structure it plays a non-ignorable role in the control of RNA export translation and degradation facilitating the precise regulation of genetic information flow within cells. Its presence in the methyltransferase complex highlights its importance in cell biology.
PCIF1 plays a prominent role in the mRNA capping and processing pathways. It partners with proteins such as RNA polymerase II in the pathway to ensure successful transcription and subsequent RNA modifications. The involvement in the mRNA cap methylation pathway highlights its connection with transcription and subsequent mRNA fate marking it as an important regulator in post-transcriptional gene expression regulation.
PCIF1 has been associated with conditions such as cancer and neurodegenerative diseases. Altered expression or function of PCIF1 can disrupt normal cellular processes leading to the progression of these disorders. Studies link PCIF1 changes to irregular mRNA methylation patterns which may relate to oncogenic transformation or neuronal dysfunction. Related proteins like RNA polymerase II also play important roles in understanding these disease mechanisms as they interact within the same pathways disrupted during disease states.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
This blot (lane 3 and 4) was developed using a higher sensitivity ECL substrate.
Exposure time: 3 minutes.
All lanes: Western blot - Anti-PCIF1 antibody [EPR24319-21] (ab271081) at 1/1000 dilution
Lane 1: 293T (human embryonic kidney epithelial cell) whole cell lysate at 20 µg
Lane 2: MCF-7 (human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 3: HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 4: Jurkat (human T cell leukemia T lymphocyte) whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 81 kDa
Observed band size: 85 kDa
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes.
All lanes: Western blot - Anti-PCIF1 antibody [EPR24319-21] (ab271081) at 1/1000 dilution
All lanes: Human testis tissue lysate at 20 µg
All lanes: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 81 kDa
Observed band size: 85 kDa
PCIF1 was immunoprecipitated from 0.35 mg MCF-7 (human breast adenocarcinoma epithelial cell) whole cell lysate 10 ug with ab271081 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab271081 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: MCF-7 (human breast adenocarcinoma epithelial cell) whole cell lysate 10 ug
Lane 2: ab271081 IP in MCF-7 whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab271081 in MCF-7 whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 24 seconds
This blot was developed using a higher sensitivity ECL substrate.
All lanes: Immunoprecipitation - Anti-PCIF1 antibody [EPR24319-21] (ab271081)
Predicted band size: 81 kDa
Observed band size: 85 kDa
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes.
All lanes: Western blot - Anti-PCIF1 antibody [EPR24319-21] (ab271081) at 1/1000 dilution
Lane 1: Rat liver tissue lysate at 20 µg
Lane 2: Rat testis tissue lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 81 kDa
Observed band size: 85 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com